The Role of LIN28B Signaling in Mediating the Oncogenic Phenotype in Neuroblas

LIN28B 信号传导在介导神经细胞致癌表型中的作用

• 批准号: 9238758
• 负责人: Robert Walter Schnepp
• 金额: $ 16.83万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-10-15 至 2021-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9238758
• 关键词: Ablation; Adult; Advisory Committees; Affect; Aggressive behavior; Animal Disease Models; Apoptosis; Autologous Stem Cell Transplantation; Award; Binding; Binding Proteins; Bioinformatics; Biological Assay; CRISPR/Cas technology; Cell Cycle; Cell Cycle Progression; Cell Line; Cell Proliferation; Cells; Childhood; Clinical; Code; Combined Modality Therapy; Data; Development; Disease; Embryonic Development; Employee Strikes; Enzymes; Exhibits; Family; Foundations; Future; Genes; Glycolysis; Goals; Grant; Guanosine Triphosphate Phosphohydrolases; Hematopoietic stem cells; Heterogeneity; High-Throughput Nucleotide Sequencing; Immunoprecipitation; Immunotherapy; In Vitro; Infection; K-Series Research Career Programs; Laboratories; Literature; Malignant Neoplasms; Mediating; Mentors; Mentorship; Messenger RNA; Metabolism; MicroRNAs; Modeling; Nephroblastoma; Nervous system structure; Neuroblastoma; Oncogenic; Operative Surgical Procedures; Oxidative Phosphorylation; Pathway interactions; Patient risk; Patients; Phenocopy; Phenotype; Play; Property; Proteins; Publishing; RAS Superfamily Proteins; RNA-Binding Proteins; Radiation; Research; Role; STK6 gene; Signal Transduction; Small RNA; Study models; Sympathetic Nervous System; Technology; Testing; Therapeutic; Transplantation; Tumor Initiators; Tumor Suppressor Proteins; Untranslated RNA; Work; Xenograft procedure; aurora-A kinase; base; cancer genetics; career; career development; cellular transduction; chemotherapy; chromosome 12q gain; crosslink; crosslinking and immunoprecipitation sequencing; defined contribution; experimental study; fetal; genetic signature; high risk; high throughput technology; improved; in vivo; insight; malignant phenotype; mortality; neuroblastoma cell; novel; oncology; protein function; public health relevance; ran GTP-Binding Protein; self-renewal; stem cell biology; subcutaneous; transcriptome sequencing; tumor; tumor initiation; tumor progression; tumor xenograft; tumorigenesis

 DESCRIPTION (provided by applicant): Neuroblastoma illustrates the striking clinical heterogeneity that one tumor histotype can encompass, with stage 4S patients undergoing spontaneous tumor regression and high-risk patients exhibiting significant mortality. Our laboratory recently identified LIN28B, an RNA binding protein that inhibits the let-7 tumor suppressor microRNA family and binds mRNAs directly, as an oncogenic driver in neuroblastoma. While its roles in metabolism and embryonic development are becoming increasingly well-understood, how it promotes oncogene- sis is less clear. We have shown that LIN28B drives expression of the Ras-related protein RAN and Aurora kinase A (AURKA), to promote neuroblastoma proliferation. We also have evidence indicating that LIN28B promotes stemless related gene signatures in neuroblastoma, raising the possibility that its function in promoting self-renewal in normal development may also serve an oncogenic role. This Mentored Career Development proposal will test the hypothesis that LIN28B, in conjunction with RAN and AURKA, promotes cell proliferation and self-renewal to drive neuroblastoma aggression. First, we will determine the mechanisms by which LIN28B promotes self-renewal. Second, we will dissect the contribution of the downstream LIN28B targets RAN and AURKA to cell proliferation and self-renewal. In the final aim, we will test the hypothesis that LIN28B binding to mRNAs, including mRNAs of the RAN signaling network, provides one mechanism by which it exerts its oncogenic function. This K08 Award will broaden my scientific repertoire and provide an outstanding basis for a career in basic and translational oncology. First, in Aims 1 and 2, I will develop new expertise on the role of LIN28B/let-7 in mediating self-renewal, a hallmark of cancer that may represent an eventual therapeutic vulnerability but that re- quires further study. Second, I will master RNA-Seq and related technologies, using it to generate and test hypotheses; in Aim 1, I will use RNA-Seq to unveil the pathways LIN28B utilizes to regulate self-renewal. Finally, in Aim 3, I will develop expertise in utilizing CLIP-Seq, a high-throughput technology that identifies RNAs to which RNA binding proteins bind. This will further our understanding of coding and non-coding RNAs influenced by LIN28B and may improve our understanding of how other RNA binding proteins function. This work will be completed under the outstanding mentorship of Dr. John Maris and an Advisory Committee, comprised of Drs. Anil Rustgi, Celeste Simon, Andrei Thomas-Tikhonenko, Tom Look, and Sharon Diskin. Collectively, this committee possesses expertise in cancer genetics, RNA binding proteins, microRNAs, stem cell biology, bioinformatics, and animal models of disease. By studying this key pathway in neuroblastoma, I aim to lay the basis for its eventual therapeutic manipulation and generate novel insights to further our understanding of both pediatric and adult malignancies. In summary, both the scientific and educational components of this grant will strengthen my scientific foundation, allowing me to launch an independent research career.

 描述（由申请人提供）：神经母细胞瘤说明了一种肿瘤组织型可能包含的显著临床异质性，4S期患者发生自发肿瘤消退，高危患者显示显著死亡率。我们的实验室最近发现LIN 28 B，一种RNA结合蛋白，抑制let-7肿瘤抑制microRNA家族并直接结合mRNA，作为神经母细胞瘤的致癌驱动因子。虽然它在代谢和胚胎发育中的作用越来越被人们所了解，但它如何促进癌基因的表达尚不清楚。我们已经表明，LIN 28 B驱动Ras相关蛋白RAN和极光激酶A（AURKA）的表达，以促进神经母细胞瘤增殖。我们也有证据表明LIN 28 B促进神经母细胞瘤中的无茎相关基因签名，这提高了其在正常发育中促进自我更新的功能也可能起到致癌作用的可能性。这个指导职业发展建议将测试LIN 28 B与RAN和AURKA一起促进细胞增殖和自我更新以驱动神经母细胞瘤攻击的假设。首先，我们将确定LIN 28 B促进自我更新的机制。其次，我们将剖析下游LIN 28 B靶点RAN和AURKA对细胞增殖和自我更新的贡献。在最后的目标，我们将测试的假设，LIN 28 B结合mRNA，包括RNA信号网络的mRNA，提供了一种机制，它发挥其致癌功能。这个K 08奖将扩大我的科学技能，并为基础和转化肿瘤学的职业生涯提供出色的基础。首先，在目标1和2中，我将开发关于LIN 28 B/let-7在介导自我更新中的作用的新专业知识，这是癌症的标志，可能代表最终的治疗脆弱性，但需要进一步研究。其次，我将掌握RNA-Seq和相关技术，使用它来生成和测试假设;在目标1中，我将使用RNA-Seq来揭示LIN 28 B用于调节自我更新的途径。最后，在目标3中，我将发展利用CLIP-Seq的专业知识，CLIP-Seq是一种高通量技术，可以识别RNA结合蛋白结合的RNA。这将进一步加深我们对LIN 28 B影响的编码和非编码RNA的理解，并可能提高我们对其他RNA结合蛋白功能的理解。这项工作将在John Maris博士和一个咨询委员会的出色指导下完成，该委员会由Anil Rustgi，塞莱斯特西蒙，Andrei Rustas-Tikhonenko，Tom Look和Sharon Diskin博士组成。总的来说，该委员会拥有癌症遗传学，RNA结合蛋白，microRNA，干细胞生物学，生物信息学和疾病动物模型的专业知识。通过研究神经母细胞瘤中的这一关键途径，我的目标是为其最终的治疗操作奠定基础，并产生新的见解，以进一步了解儿童和成人恶性肿瘤。总而言之，这笔赠款的科学和教育部分将加强我的科学基础，使我能够开始独立的研究生涯。